Pfizer cans PF-08046045, but keeps PF-08046044 for now.
ApexOnco Front Page
Recent articles
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
The company is stepping back in second-line breast cancer.
First-in-human study listings include EOS-215 and RO7673396.
The company’s matching strategy for CB-010 will soon be put to the test.
Vobra-duo is discontinued at long last.
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
After Astra's EsoBiotec takeover the battle for uniqueness begins.
